Opigolix

Opigolix (INN, USAN; developmental code name ASP-1707) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which was under development by Astellas Pharma for the treatment of endometriosis and rheumatoid arthritis.[1][2] It was also under investigation for the treatment of prostate cancer.[1] It reached phase II clinical trials for both endometriosis and rheumatoid arthritis prior to the discontinuation of its development in April 2018.[1]

Opigolix
Clinical data
Other namesASP-1707
Routes of
administration
By mouth
Drug classGnRH modulator; GnRH antagonist; Antigonadotropin
Identifiers
CAS Number
PubChem CID
UNII
KEGG
Chemical and physical data
FormulaC25H19F3N4O5S
Molar mass544.505 g/mol g·mol−1
3D model (JSmol)

See also

References

  1. http://adisinsight.springer.com/drugs/800032657
  2. Ezzati M, Carr BR (2015). "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Womens Health (Lond). 11 (1): 19–28. doi:10.2217/whe.14.68. PMID 25581052.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.